West Vancouver

Researchers are evaluating lunsekimig, a subcutaneous injection, compared with placebo in adults aged 40 to 80 years with inadequately controlled Chronic Obstructive Pulmonary Disease COPD characterized by an eosinophilic phenotype. This Phase 2bPhase 3 parallel study aims to assess the efficacy, safety, and tolerability of lunsekimig in reducing COPD exacerbations and improving lung function and symptoms. Participants are randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a 48-week treatment period. The study also includes a screening period of up to 4 weeks before treatment and an approximately 8-week follow-up period after treatment, totaling up to 60 weeks of participation. During the study, participants will undergo regular assessments including lung function tests such as post- and pre-bronchodilator Forced Expiratory Volume in 1 second FEV1, questionnaires measuring respiratory health and symptoms, and monitoring of COPD exacerbations. Safety will be evaluated through reported adverse events and laboratory tests. Researchers will also monitor blood levels of lunsekimig and the presence of antidrug antibodies. Participants will be followed closely throughout the study duration to assess treatment impact and safety.

Indigenous people living in rural and remote communities across Manitoba, British Columbia, Alberta, Saskatchewan, and Ontario face higher risks of Chronic Kidney Disease CKD, diabetes, and high blood pressure compared to the general population. This research aims to perform point-of-care testing to identify these conditions early and provide tailored treatment plans. The study seeks to develop a durable CKD surveillance system to reduce the burden of kidney disease and kidney failure in these communities. Participants will receive point-of-care screening conducted by a registered nurse, including demographic and physical data collection, and blood and urine testing. Results are provided during the appointment, and those at high risk of kidney failure are referred to nephrologists, while others receive guidance for primary care follow-up. This approach supports early diagnosis and treatment in both adults and children. Throughout the study, participants will undergo assessments of kidney function biomarkers, diabetes status, blood pressure, and kidney failure risk during the screening visit. The process includes real-time testing and counseling, aiming to ensure ongoing care and monitoring. The total involvement includes one screening day, with follow-up care coordinated based on individual risk levels to help prevent CKD progression and kidney failure.